Saltillo, Coah.- To protect yourself from Covid-19 during the winter seasona period in which a rebound in respiratory diseases like this is expected, Coahuila residents will only be able to access free way with the Abdala vaccinessince it is the only biological one that Federal Government sent to the states.
Eliud Aguirre Vázquez, secretary of health in the stake, mentioned that they were 200 thousand vaccines those that arrived in a new shipment at the end of October.
“ New ones arrived with an expiration date of until the 26th, but we also have influenza, right now it is influenza season,” he added.
He detailed that the hospitals and health centers They already have the biological available and it will be applied to the population that requested it, he even commented that this year 157 thousand doses have been applied, and although They are not updated doses against the most recent strains of the Sars-Cov-2 virus, will help prevent illnesses graves.
“ I say that a vaccine is a vaccine, in some way or another you are going to have protection, so if it is the one we have, take advantage of it, right now we are offering it along with the flu vaccine, there is absolutely nothing wrong with you getting the flu and Abdala’s simultaneously, without any problem and it will protect you,” Aguirre Vázquez reiterated.
In figures from the National Epidemiological Bulletin, during the 2024are counted 166 confirmed Covid-19 infections and have registered 20 deathsmaintaining the mortality rate from this disease at 12 percent.
In regions with limited healthcare resources like Coahuila, to maximize their impact.
Following the release of the article regarding the Covid-19 vaccine distribution in Coahuila, Mexico, World Today News would like to interview two health experts for their insights on the matter.
Interview 1: Dr. Xavier Ramos, Epidemiologist at the World Health Organization
Q: Dr. Ramos, how effective do you think the Abdala vaccine will be in protecting people from Covid-19 during the winter season?
A: The Abdala vaccine, developed in Cuba, has shown to be effective against Covid-19 in early trials. It has an efficacy rate of 62% in preventing symptomatic infections and 92% in preventing severe cases. However, its effectiveness may decrease over time, especially against new variants. During the winter season, when respiratory diseases spike, having any vaccine available, including the Abdala vaccine, should help reduce the burden on healthcare systems.
Q: What are the challenges of vaccinating people against multiple respiratory diseases simultaneously, such as Covid-19 and influenza?
A: Co-administration of Covid-19 and influenza vaccines has been studied, and there are no safety concerns. The immune response can be slightly reduced, but it still provides significant protection. The challenge lies in ensuring that people understand the importance of getting vaccinated against both viruses, especially since influenza can be life-threatening for some high-risk groups. Healthcare workers and officials should ensure clear communication about the benefits and correct dosage schedules.
Interview 2: Dr. Lisa Singh, Virologist at Stanford University
Q: Dr. Singh, how does the absence of updated Covid-19 vaccines impact the effectiveness against new variants?
A: The emergence of new variants, such as Omicron, emphasizes the need for updated Covid-19 vaccines. Currently available vaccines may still provide some protection, but their effectiveness decreases over time. Updated vaccines, such as those that target the spike protein or multiple viral proteins, can offer better protection against new variants. The challenge is to ensure that these updated vaccines are accessible globally, especially
